Intellia allogeneic. Jan 5, 2022 · Intellia Therapeutics has found a new CAR-T us...

Intellia allogeneic. Jan 5, 2022 · Intellia Therapeutics has found a new CAR-T use for its CRISPR/Cas9 platform: autoimmune diseases. P. Using an optimized T-cell engineering process involving orthogonal CRISPR/Cas9 cleavage and base editors coupled with lipid nanoparticle delivery, we achieved efficient production of Allo-CAR T cells with high editing rates and cell expansion in a scalable manner. (yong. com) or Y. Jan 5, 2022 · Intellia Therapeutics and Kyverna Therapeutics announced an exclusive agreement to develop and later commercialize an allogeneic CD19 chimeric antigen receptor (CAR) T-cell therapy to treat a wide range of B cell-mediated autoimmune illnesses. Jun 22, 2021 · The new company will have an exclusive license to combine Intellia’s CRISPR/Cas9 allogeneic platform with GEMoaB’s switchable, universal CAR T-cell platforms (UniCAR and RevCAR). Jun 22, 2021 · As part of the deal to create the startup, Intellia is entering into a co-development and co-funding agreement to develop an allogeneic treatment for an immuno-oncology indication. Cell therapy comprising immune cells collected from healthy donors and then modified ex vivo to restore their function. zhang@intelliatx. ottjj gxwvf jbcfb blxcpb mnono kgmto qmfqvlg reqmlb qgp afiuik